Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among US adults, utilization of pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) has increased more than ninefold since 1995-1996. Potential contraindications to ADHD pharmacotherapy include serious cardiovascular disease (CVD) and, for stimulants, addictions and bipolar disorder (BPD). OBJECTIVE: To assess the prevalence of potential contraindications among adults treated with ADHD pharmacotherapy. METHODS: database. Subjects filled ≥ 1 prescription for atomoxetine or ≥ 1 stimulant in 2014-2015, were aged 18-64 years, commercially insured throughout observation, and diagnosed with ADHD on two or more medical claims. Diagnoses and medical procedures were measured in the 12 months prior to pharmacotherapy initiation. Metrics included serious CVD (cardiomegaly, cardiomyopathy, cerebrovascular occlusion, congestive heart failure, myocardial infarction, pacemaker, or valvular disorder) and any CVD (serious CVD, other atherosclerotic CVD, arrhythmia, congenital heart anomaly, or hypertensive heart disease). Rates of substance addiction or abuse were measured in a range to address nonspecific diagnostic coding. RESULTS: Only 2.0% of treated adults (n = 91,588) had one or more diagnosis indicating serious CVD. CVD prevalence increased monotonically with age. Of patients aged 55-64 years (n = 5,237), 7.2% had serious CVD; 15.9% had any CVD; and 1.9% had been hospitalized with one or more CVD. Of patients treated with stimulants (n = 87,167), 11.3-18.5% were diagnosed with addiction/abuse and 4.1% with BPD. CONCLUSIONS: CVD prevalence is generally low among adults using ADHD medication but increases with age. Although difficult to estimate precisely, the rate of addiction/abuse among stimulant-treated patients appears unexpectedly high. Further research should assess cardiovascular events and other potential harms associated with contraindicated use in high-risk adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, poor responsiveness, pharmacological tolerance, risk of poisoning, high risk of misuse and improper use (e.g. despite contraindications) are common concerns of ADHD medications21–23.”
From Effects of l-theanine–caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT (2020) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 1×
“Use of lisdexamfetamine did not qualify patients for the sample because it has a labeled indication for binge-eating disorder [35], an obesity-related condition that is associated with CVD risk factors including diabetes, hypertension, and dyslipidemias [36, 37].”
BackgroundThe D 2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome
Blum, K., Sheridan, P. J., Wood, R. C., Braverman, E. R., Chen, T. J. H., phd, J. G. C., & Comings, D. E. (1996) · Journal of the Royal Society of Medicine · doi:10.1177/014107689608900711 · Cited by 443 · cited 1×
“, the phenomenon known as ‘‘addiction transfer’’) [55, 56].”
ADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331 · cited 2×
“Because this expansion would result in ‘‘the administration of potent sympathomimetic agents to millions of Americans,’’ the editorialist noted, the committee ‘‘sought to emphasize more selective and restricted use, while increasing awareness of potential hazards’’ [54].”
BackgroundRelationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome
Bowirrat, A., & Oscar‐Berman, M. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30080 · Cited by 301
ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1830 · Cited by 297 · cited 5×
“for ‘‘alcohol/substance abuse’’ in 1986–2007 [31].”
BackgroundResultInfluentialMcCabe, S. E., West, B. T., Teter, C. J., & Boyd, C. J. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.03.008 · Cited by 268
The deliberate misdiagnosis of major depression in primary care
Rost, K. (1994) · Archives of Family Medicine · doi:10.1001/archfami.3.4.333 · Cited by 263
Medical comorbidity of binge eating disorder
Olguín, P., Fuentes, M., Gabler, G., Guerdjikova, A. I., Keck, P. E., & McElroy, S. L. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0313-5 · Cited by 164
Cited by
Kahathuduwa, C. N., Wakefield, S., West, B. D., Blume, J., Dassanayake, T. L., Weerasinghe, V. S., & Mastergeorge, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-70037-7 · Cited by 45
Attention deficit/hyperactivity disorder in adults: A case study
Plowden, K. O., Legg, T. J., & Wiley, D. (2022) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2021.12.003 · Cited by 14
Yan, Y., Chen, Q., Nasir, R., Griffin, P. M., Bone, C., & Tuan, W. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109870 · Cited by 2
Fairman, K. A. (2020) · ScholarWorks (Walden University)
Self-citationCVD prevalence low in patients receiving ADHD medication
(2018) · Reactions Weekly · doi:10.1007/s40278-018-41074-6
Metadata
- Authors
- Fairman, K. A., Davis, L. E., Peckham, A. M., & Sclar, D. A.
- Affiliations
- Midwestern University (US)
- Corresponding author
- Fairman, Kathleen A.
- Venue
- Drugs - Real World Outcomes
- Published
- 2018-01-05
- Volume
- 5
- Issue
- 1
- Pages
- 69-79
- ISSN
- 2198-9788 (ISSN-L)
- 2199-1154
- PMC
- PMC5825392
- OpenAlex
- W2781587598
- Cited by
- 5
- References
- 39
- Citations by year
- 2025: 2 · 2022: 1 · 2020: 1 · 2018: 1
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drugs - Real World Outcomes (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Midwestern University
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- attention deficit hyperactivity disorder, ADHD medication, stimulants, atomoxetine, cardiovascular disease, substance addiction, bipolar disorder, contraindications, product labeling, adults, age differences, commercial insurance claims
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? https://app.cochat.ai/papers/10.1007/s40801-017-0129-2
- The paper
- Fairman, K. A., Davis, L. E., Peckham, A. M., & Sclar, D. A. (2018). Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Drugs - Real World Outcomes. https://doi.org/10.1007/s40801-017-0129-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
